Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone
Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The object...
Gespeichert in:
Veröffentlicht in: | Value in health 2015-09, Vol.18 (6), p.759-766 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 766 |
---|---|
container_issue | 6 |
container_start_page | 759 |
container_title | Value in health |
container_volume | 18 |
creator | Gerhardsson de Verdier, Maria, MD, PhD Andersson, Maria, PhD Kern, David M., MS Zhou, Siting, PhD Tunceli, Ozgur, PhD |
description | Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition. |
doi_str_mv | 10.1016/j.jval.2015.04.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717473888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301515019361</els_id><sourcerecordid>1717473888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</originalsourceid><addsrcrecordid>eNp9kU2P0zAQhiMEYpeFP8AB-cglwXbiJEYIqeryJa3UlRbOlmNPVAcnLnZS1H_PhBYOHLh4PPY7rz3PZNlLRgtGWf1mKIaj9gWnTBS0Kiijj7JrJniVV01ZPsY9lW1e4vVV9iylgVJal1w8za54XVFZU36dnTZp3o-a6MmS7T6GyRmy69IcFzO7I5D7xY9h0vFEbl0CnYDsjhC9PpCH02RjGOEtuQ1L5wHrQ5oTruNBR0x_unlP7vXsYMLj39nlsY0PEzzPnvTaJ3hxiTfZt48fvm4_53e7T1-2m7vcCC7m3NJWylpWLZfGMoytxM93HTbQ94w1zGowurS97JqqllwI2hgLnZCN7WpeljfZ67PvIYYfC6RZjS4Z8F5PEJak0KJBXm3bopSfpSaGlCL06hDdiM0rRtWKXA1qRa5W5IpWCpFj0auL_9KNYP-W_GGMgndnAWCXRwdRJYNMDFgXwczKBvd___f_lBvvcEzaf4cTpCEscUJ-iqnEFVUP69DXmTNBmSxrVv4C0-2nxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1717473888</pqid></control><display><type>article</type><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</creator><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</creatorcontrib><description>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2015.04.010</identifier><identifier>PMID: 26409602</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Asthmatic Agents - economics ; Anti-Asthmatic Agents - therapeutic use ; asthma ; Asthma - diagnosis ; Asthma - economics ; Asthma - epidemiology ; Asthma - therapy ; Child ; claims data ; Comorbidity ; COPD ; Costs and Cost Analysis ; Disease Progression ; Drug Costs ; Emergency Service, Hospital - economics ; Female ; Health Care Costs ; Health Resources - economics ; Health Resources - utilization ; Hospitalization - economics ; Humans ; Internal Medicine ; Male ; Middle Aged ; Models, Economic ; overlap syndrome ; Prevalence ; Prognosis ; Pulmonary Disease, Chronic Obstructive - complications ; Pulmonary Disease, Chronic Obstructive - economics ; Pulmonary Disease, Chronic Obstructive - epidemiology ; Pulmonary Disease, Chronic Obstructive - therapy ; Retrospective Studies ; Risk Factors ; Syndrome ; Time Factors ; United States - epidemiology ; Young Adult</subject><ispartof>Value in health, 2015-09, Vol.18 (6), p.759-766</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</citedby><cites>FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</cites><orcidid>0000-0003-1968-6551</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jval.2015.04.010$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26409602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD</creatorcontrib><creatorcontrib>Andersson, Maria, PhD</creatorcontrib><creatorcontrib>Kern, David M., MS</creatorcontrib><creatorcontrib>Zhou, Siting, PhD</creatorcontrib><creatorcontrib>Tunceli, Ozgur, PhD</creatorcontrib><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Asthmatic Agents - economics</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - economics</subject><subject>Asthma - epidemiology</subject><subject>Asthma - therapy</subject><subject>Child</subject><subject>claims data</subject><subject>Comorbidity</subject><subject>COPD</subject><subject>Costs and Cost Analysis</subject><subject>Disease Progression</subject><subject>Drug Costs</subject><subject>Emergency Service, Hospital - economics</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Health Resources - economics</subject><subject>Health Resources - utilization</subject><subject>Hospitalization - economics</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Models, Economic</subject><subject>overlap syndrome</subject><subject>Prevalence</subject><subject>Prognosis</subject><subject>Pulmonary Disease, Chronic Obstructive - complications</subject><subject>Pulmonary Disease, Chronic Obstructive - economics</subject><subject>Pulmonary Disease, Chronic Obstructive - epidemiology</subject><subject>Pulmonary Disease, Chronic Obstructive - therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Syndrome</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><subject>Young Adult</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2P0zAQhiMEYpeFP8AB-cglwXbiJEYIqeryJa3UlRbOlmNPVAcnLnZS1H_PhBYOHLh4PPY7rz3PZNlLRgtGWf1mKIaj9gWnTBS0Kiijj7JrJniVV01ZPsY9lW1e4vVV9iylgVJal1w8za54XVFZU36dnTZp3o-a6MmS7T6GyRmy69IcFzO7I5D7xY9h0vFEbl0CnYDsjhC9PpCH02RjGOEtuQ1L5wHrQ5oTruNBR0x_unlP7vXsYMLj39nlsY0PEzzPnvTaJ3hxiTfZt48fvm4_53e7T1-2m7vcCC7m3NJWylpWLZfGMoytxM93HTbQ94w1zGowurS97JqqllwI2hgLnZCN7WpeljfZ67PvIYYfC6RZjS4Z8F5PEJak0KJBXm3bopSfpSaGlCL06hDdiM0rRtWKXA1qRa5W5IpWCpFj0auL_9KNYP-W_GGMgndnAWCXRwdRJYNMDFgXwczKBvd___f_lBvvcEzaf4cTpCEscUJ-iqnEFVUP69DXmTNBmSxrVv4C0-2nxQ</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Gerhardsson de Verdier, Maria, MD, PhD</creator><creator>Andersson, Maria, PhD</creator><creator>Kern, David M., MS</creator><creator>Zhou, Siting, PhD</creator><creator>Tunceli, Ozgur, PhD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1968-6551</orcidid></search><sort><creationdate>20150901</creationdate><title>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</title><author>Gerhardsson de Verdier, Maria, MD, PhD ; Andersson, Maria, PhD ; Kern, David M., MS ; Zhou, Siting, PhD ; Tunceli, Ozgur, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-d0899694829cd194889640bb409ff1171daeca3df9b746925507cdeb597db6233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Asthmatic Agents - economics</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - economics</topic><topic>Asthma - epidemiology</topic><topic>Asthma - therapy</topic><topic>Child</topic><topic>claims data</topic><topic>Comorbidity</topic><topic>COPD</topic><topic>Costs and Cost Analysis</topic><topic>Disease Progression</topic><topic>Drug Costs</topic><topic>Emergency Service, Hospital - economics</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Health Resources - economics</topic><topic>Health Resources - utilization</topic><topic>Hospitalization - economics</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Models, Economic</topic><topic>overlap syndrome</topic><topic>Prevalence</topic><topic>Prognosis</topic><topic>Pulmonary Disease, Chronic Obstructive - complications</topic><topic>Pulmonary Disease, Chronic Obstructive - economics</topic><topic>Pulmonary Disease, Chronic Obstructive - epidemiology</topic><topic>Pulmonary Disease, Chronic Obstructive - therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Syndrome</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerhardsson de Verdier, Maria, MD, PhD</creatorcontrib><creatorcontrib>Andersson, Maria, PhD</creatorcontrib><creatorcontrib>Kern, David M., MS</creatorcontrib><creatorcontrib>Zhou, Siting, PhD</creatorcontrib><creatorcontrib>Tunceli, Ozgur, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerhardsson de Verdier, Maria, MD, PhD</au><au>Andersson, Maria, PhD</au><au>Kern, David M., MS</au><au>Zhou, Siting, PhD</au><au>Tunceli, Ozgur, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>18</volume><issue>6</issue><spage>759</spage><epage>766</epage><pages>759-766</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Abstract Background Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients. Objective The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS. Methods This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation. Results Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group. Conclusions Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26409602</pmid><doi>10.1016/j.jval.2015.04.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1968-6551</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1098-3015 |
ispartof | Value in health, 2015-09, Vol.18 (6), p.759-766 |
issn | 1098-3015 1524-4733 |
language | eng |
recordid | cdi_proquest_miscellaneous_1717473888 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present) |
subjects | Adolescent Adult Aged Anti-Asthmatic Agents - economics Anti-Asthmatic Agents - therapeutic use asthma Asthma - diagnosis Asthma - economics Asthma - epidemiology Asthma - therapy Child claims data Comorbidity COPD Costs and Cost Analysis Disease Progression Drug Costs Emergency Service, Hospital - economics Female Health Care Costs Health Resources - economics Health Resources - utilization Hospitalization - economics Humans Internal Medicine Male Middle Aged Models, Economic overlap syndrome Prevalence Prognosis Pulmonary Disease, Chronic Obstructive - complications Pulmonary Disease, Chronic Obstructive - economics Pulmonary Disease, Chronic Obstructive - epidemiology Pulmonary Disease, Chronic Obstructive - therapy Retrospective Studies Risk Factors Syndrome Time Factors United States - epidemiology Young Adult |
title | Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A44%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asthma%20and%20Chronic%20Obstructive%20Pulmonary%20Disease%20Overlap%20Syndrome:%20Doubled%20Costs%20Compared%20with%20Patients%20with%20Asthma%20Alone&rft.jtitle=Value%20in%20health&rft.au=Gerhardsson%20de%20Verdier,%20Maria,%20MD,%20PhD&rft.date=2015-09-01&rft.volume=18&rft.issue=6&rft.spage=759&rft.epage=766&rft.pages=759-766&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2015.04.010&rft_dat=%3Cproquest_cross%3E1717473888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1717473888&rft_id=info:pmid/26409602&rft_els_id=S1098301515019361&rfr_iscdi=true |